chufangao/CTO huggingface dataset:
Clinical trial NCT03410056: Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
Official title: A Phase 1b/2a Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Amgen made a business decision not to proceed with Phase 2.
Enrollment: 36.0 (ACTUAL)
Number of arms: 7.0
Start date: 2018-05-22
Primary completion date: 2019-12-10
Completion date: 2020-05-13
Baseline population: The safety analysis set: All participants who received at least 1 dose of investigational product.~Only cohorts with enrolled participants are included in the baseline population.
Limitations and caveats: Enrollment of the phase 1b part of this study was stopped as of 30 September 2019 due to data that suggested that there is not sufficient benefit-risk for the use of Efavaleukin alfa plus standard of care therapy in this study population. The study was terminated prior to the enrollment of any participants into phase 1b Cohort 4 and phase 2a cohorts.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Clinical trial NCT03852992: Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia
Official title: The Safety and Efficacy of Fractional Ablative 10, 600nm CO2 Laser-assisted Treatments for Male Pattern Hair Loss: a Randomized Cohort Study Comparing Stand-alone Laser Treatment, Laser Assisted Drug Delivery of Minoxidil 2% Solution , and Laser Assisted Drug Delivery of Minoxidil 2% Solution Plus Self-administration of Minoxidil 5% at Home.
Sponsor: University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study was closed with IRB on 10/22/22
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-09-30
Primary completion date: 2023-07-01
Completion date: 2023-07-01
Plan to share individual participant data: NO
Clinical trial NCT05009953: Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
Official title: An Open-label, Multicentre, Phase II Study to Evaluate the Safety and Efficacy of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Internal strategy change. Not related to safety concerns.
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-01
Primary completion date: 2023-01-16
Completion date: 2023-01-16
Plan to share individual participant data: NO
Clinical trial NCT03145558: TATE Versus TACE in Intermediate Stage HCC
Official title: TATE Versus TACE, an Open-label Randomized Study Comparing TransArterial Tirapazamine Embolization Versus TransArterial ChemoEmbolization in Intermediate Stage Hepatocellular Carcinoma
Acronym: TATE
Sponsor: Teclison Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: on hold by sponsor
Enrollment: 134.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2017-12-05
Primary completion date: 2024-12-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT02712905: An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Official title: A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Strategic Business Decision
Enrollment: 116.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-05-05
Primary completion date: 2022-04-14
Completion date: 2022-04-14
Limitations and caveats: The study was terminated by the sponsor due to a strategic business decision.
Clinical trial NCT02699138: Obstructive Sleep Apnea and Arousal Threshold in Patients With Post-traumatic Stress Disorder
Official title: Obstructive Sleep Apnea and Arousal Threshold in Patients With Post-traumatic
Sponsor: University of California, San Diego (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Research fellow left institution
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-31
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Clinical trial NCT03230916: A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)
Official title: A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Infections
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 47.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-11-06
Primary completion date: 2020-07-28
Completion date: 2020-08-11
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03272633: Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
Official title: Post-Transplant Use of Irradiated Haplo-Allogeneic Cells
Sponsor: Rutgers, The State University of New Jersey (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Lack of enrollment
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-26
Primary completion date: 2022-06-30
Completion date: 2022-09-22
Baseline population: No participants qualified for cohort I
Clinical trial NCT04330638: Treatment of COVID-19 Patients With Anti-interleukin Drugs
Official title: A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome
Acronym: COV-AID
Sponsor: University Hospital, Ghent (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 342.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-04-03
Primary completion date: 2020-12-20
Completion date: 2021-05-21
Baseline population: The study investigates IL-6 and IL-1 blockade 339 participants received IL Blockade: 227 participants IL-6 blockade + 112 participants IL-1 blockade; 345 participants No Blockade: 230 participants no IL-6 blockade + 115 participants no IL-1 blockade
Plan to share individual participant data: NO
Clinical trial NCT03284723: PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors
Official title: A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive and Negative Solid Tumors
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The trial was terminated based on the stage in drug development and assessment of PF-06804103 relative to the leading external competition. The decision was not due to a safety concern.
Enrollment: 95.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-01
Primary completion date: 2021-08-31
Completion date: 2021-08-31
Baseline population: Baseline analysis population included all enrolled participants who received at least one dose of study treatment.
Limitations and caveats: On 10 February 2021, a decision was made by the sponsor to terminate the study due to business reasons. The decision was not due to any urgent patient safety concerns, study conduct issues, or regulatory authority requests concerning treatment with the PF-06804103 compound. Part 2B had not enrolled prior to the termination of the study.
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04023240: 68-Ga-FAPI PET Imaging in Malignancy
Official title: 68Ga-FAPI PET Imaging in Malignancy
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: no patients enrolled into study
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-07-31
Primary completion date: 2023-07-14
Completion date: 2023-12-14
Plan to share individual participant data: NO
Clinical trial NCT04402385: Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)
Official title: Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Unable to recruit.
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-06
Primary completion date: 2022-06-22
Completion date: 2022-06-22
Baseline population: Participants from the initially enrolled that delivered successfully.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03334656: Controlled Comparison of a Traditional Dressing Versus a Biologic Dressing Composed of Fetal Fibroblasts and Keratinocytes in Association With a Collagen Matrix on Skin Donor Sites
Official title: Controlled Comparison of a Traditional Dressing Versus a Biologic Dressing Composed of Fetal Fibroblasts and Keratinocytes in Association With a Collagen Matrix on Skin Donor Sites
Acronym: CICAFAST
Sponsor: Nantes University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: It was decided to terminate the study prematurely due to insufficient enrolment, despite extensions to the enrolment period.
Enrollment: 28.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-16
Primary completion date: 2024-07-15
Completion date: 2024-07-15
Clinical trial NCT04159701: A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated for lack of efficacy after an interim analysis was performed
Enrollment: 52.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-15
Primary completion date: 2021-02-24
Completion date: 2021-02-24
Baseline population: All randomized participants.
Limitations and caveats: The study was terminated for lack of efficacy after an interim analysis was performed.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT04524195: PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)
Official title: A Study of PET Imaging of T-cell Activation With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1-directed Therapy
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study is terminated because the PI left the institution.
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-01
Primary completion date: 2023-11-27
Completion date: 2023-11-27
Plan to share individual participant data: NO
Clinical trial NCT05156671: Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial
Official title: Multicenter, Randomized, Double-blind, Biomarker-guided, Phase II Trial With Adrecizumab (HAM 8101) to Improve proGNosis and outcomES in Patients With Moderate to Severe COVID-19
Acronym: AGNES-19
Sponsor: Universitätsklinikum Hamburg-Eppendorf (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to poor recruitment.
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-06
Primary completion date: 2023-08-25
Completion date: 2023-11-15
Plan to share individual participant data: NO
Clinical trial NCT06411067: Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain
Official title: Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain
Sponsor: United States Naval Medical Center, Portsmouth (FED)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Lapse in IRB approval
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-26
Primary completion date: 2022-05-09
Completion date: 2022-05-09
Plan to share individual participant data: NO
Clinical trial NCT02565511: A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Official title: A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.
Acronym: GS1
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Enrollment: 480.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-11-30
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Baseline population: Three participants were included in the Participant Flow in Cohort II but not included in Baseline Characteristics because they were mis-randomized.
Limitations and caveats: The study was terminated due to unexpected changes in cognitive function, brain volume loss, and body weight loss. Cohort II (CNP520) treatment was stopped and evaluated through an off-treatment follow-up period. After the decision to terminate Cohort II of the study (CNP520), treatment with CAD106 (Cohort I) was also terminated
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT02851797: Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Official title: Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Sponsor: Italfarmaco (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 179.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-06
Primary completion date: 2022-02-22
Completion date: 2022-02-22
Baseline population: Number of Subjects Enrolled in Each Country (Overall Population).The all-enrolled subjects set included all subjects who were randomised to study treatment. The overall all-enrolled subjects set included all subjects in both the target and off-target populations (Group A + Group B) who were randomised to study treatment.
Plan to share individual participant data: NO
Clinical trial NCT02371577: Evaluation of the Immune Restoration Potential Of Lenalidomide
Official title: A Phase 2 Clinical Trial To Evaluate The Immune Restoration Potential Of Lenalidomide For Patients With CLL-Associated Immunodeficiency
Acronym: Revlimid
Sponsor: University of California, San Diego (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: withdrawn
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-01
Primary completion date: 2018-12-31
Completion date: 2020-12-31
Clinical trial NCT04403568: Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate
Official title: Phase I Clinical Trial Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate
Sponsor: The University of Texas Health Science Center at San Antonio (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: No subjects were enrolled in this study, the PI will seek funding and revise the protocol for resubmisson at a later date
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-10-31
Primary completion date: 2022-12-31
Completion date: 2023-12-31
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data will be available upon request.
IPD time frame: De-identified individual participant data will be available upon completion of the study for approx. 1 year.
IPD access criteria: Access granted upon request.
Clinical trial NCT04588129: Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
Official title: An Open Label Positron Emission Tomography (PET) Study to Evaluate Dopamine Receptor Occupancy of LB-102 Administered Orally to Healthy Subjects
Sponsor: LB Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 16.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-01-05
Primary completion date: 2021-09-17
Completion date: 2021-11-15
Plan to share individual participant data: NO
Clinical trial NCT04575610: IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)
Official title: Investigation of IRAK4 Inhibition to Mitigate the Impact of COVID-19 in Severe SARS-CoV-2 (I-RAMIC)
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study terminated due to lack of enrollment reflecting the decrease in number of COVID infections. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-27
Primary completion date: 2021-10-06
Completion date: 2021-10-06
Plan to share individual participant data: NO
Clinical trial NCT02664181: Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial
Official title: Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-small Cell Lung Cancer
Acronym: PRECISE
Sponsor: Case Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-06
Primary completion date: 2019-07-02
Completion date: 2024-05-19
Baseline population: Participants enrolled in study
Clinical trial NCT01597973: Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)
Official title: Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 467.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-10-06
Primary completion date: 2020-08-09
Completion date: 2020-08-09
Clinical trial NCT04404712: FAAH Availability in Psychiatric Disorders: A PET Study
Official title: FAAH Availability in Psychiatric Disorders: A PET Study
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Ligand was not effective.
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-23
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Clinical trial NCT04091581: Comparison of Tear Evaporation Rate With Systane Complete in Dry Eye and Non-Dry Eye
Official title: Comparison of Tear Evaporation Rate With Systane Complete in Dry Eye and Non-Dry Eye
Acronym: BULLDOG
Sponsor: University of Waterloo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 21.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-21
Primary completion date: 2020-02-06
Completion date: 2020-02-06
Plan to share individual participant data: NO
Clinical trial NCT05646459: Effect of Local Cannabidiol on Clinical and Inflammatory Outcomes in Periodontal Maintenance Patients.
Official title: Effect of Local Cannabidiol on Clinical and Inflammatory Outcomes in Periodontal Maintenance Patients.
Sponsor: University of Nebraska (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study was unable to obtain IRB approval because CBD was not legal in Nebraska at that time.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-05-14
Primary completion date: 2020-05-14
Completion date: 2020-05-14
Plan to share individual participant data: NO
Clinical trial NCT03864419: Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
Official title: A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in Uganda
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Closed per SRC Low Accrual Policy
Enrollment: 18.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-10-24
Primary completion date: 2023-07-26
Completion date: 2023-07-26
Plan to share individual participant data: NO